A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis
Arthritis Research & Therapy · 2024
DOI: 10.1186/s13075-024-03337-2 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Arthritis Research & Therapy, 2024. Verfasst von Stanley Cohen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, University of Texas Southwestern Medical School Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, Dallas, TX, …. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Receptors, CXCR5. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The objective of this study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF‑06835375, a potent selective afucosyl immunoglobulin G1 antibody targeting C-X-C chemokine receptor type 5 (CXCR5) that potentially depletes B cells, follicular T helper (Tfh) cells, and circulating Tfh-like (cTfh) cells, in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Methods
This first-in-human, multicenter, double-blind, sponsor-open, placebo-controlled Phase 1 study recruited patients aged 18–70 years with SLE or RA. In Part A, patients received single doses of intravenous PF-06835375 (dose range: 0.03–6 mg) or placebo in six sequential single ascending dose (SAD) cohorts. In Part B, patients received repeat doses of subcutaneous PF-06835375 (dose range: 0.3–10 mg) or placebo on Days 1 and 29 in five multiple ascending dose (MAD) cohorts. Tetanus/Diphtheria (Td) and Meningococcal B (MenB/Trumenba™) vaccines were administered at Day 4 (Td and MenB) and Week 8 (MenB only) to assess PF-06835375 functional effects. Endpoints included treatment-emergent adverse events (TEAEs), pharmacokinetic parameters, pharmacodynamic effects on B and cTfh cells, and biomarker counts, vaccine response, and exploratory differential gene expression analysis. Safety, pharmacokinetic, and pharmacodynamic endpoints are summarized descriptively. The change from baseline of B and Tfh cell-specific genes over time was calculated using a prespecified mixed-effects model, with a false discovery rate < 0.05 considered statistically significant.
Results
In total, 73 patients were treated (SAD cohorts: SLE, n = 17; RA, n = 14; MAD cohorts: SLE, n = 22; RA, n = 20). Mean age was 53.3 years. Sixty-two (84.9%) patients experienced TEAEs (placebo n = 17; PF-06835375 n = 45); most were mild or moderate. Three (9.7%) patients experienced serious adverse events. Mean t 1/2 ranged from 3.4–121.4 h (SAD cohorts) and 162.0–234.0 h (MAD cohorts, Day 29). B and cTfh cell counts generally showed dose-dependent reductions across cohorts (range of mean maximum depletion: 67.3–99.3%/62.4–98.7% [SAD] and 91.1–99.6%/89.5–98.1% [MAD], respectively). B cell-related genes and pathways were significantly downregulated in patients treated with PF-06835375.
Conclusions
These data support further development of PF-06835375 to assess the clinical potential for B and Tfh cell depletion as a treatment for autoimmune diseases.
Trial registration
ClinicalTrials.gov identifier: NCT03334851.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine, University of Texas Southwestern Medical School Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, Dallas, TX, 75231, USA. SCohen@dfwra.com.
- Pfizer Inc, Cambridge, MA, USA.
- Pinnacle Research Group, LLC, Anniston, AL, USA.
- Clinical Research of West Florida, Clearwater, FL, USA.
- Pfizer Inc, Collegeville, PA, USA.
- Pfizer Inc, Groton, CT, USA.
Zitieren
APA
Cohen, S., Beebe, J. S., Chindalore, V., Guan, S., Hassan-Zahraee, M., Saxena, M., Xi, L., Hyde, C., Koride, S., Levin, R., Lubaczewski, S., Salganik, M., Sloan, A., Stevens, E., Peeva, E., Vincent, M. S., Martin, D. A., & Chu, M. (2024). A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis. Arthritis Research & Therapy. https://doi.org/10.1186/s13075-024-03337-2
Vancouver
Cohen S, Beebe JS, Chindalore V, Guan S, Hassan-Zahraee M, Saxena M, et al. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis. Arthritis Research & Therapy. 2024. doi:10.1186/s13075-024-03337-2
BibTeX
@article{Cohen2024,
author = {Cohen, Stanley and Beebe, Jean S and Chindalore, Vishala and Guan, Shunjie and Hassan-Zahraee, Mina and Saxena, Madhurima and Xi, Li and Hyde, Craig and Koride, Sarita and Levin, Robert and Lubaczewski, Shannon and Salganik, Mikhail and Sloan, Abigail and Stevens, Erin and Peeva, Elena and Vincent, Michael S and Martin, David A and Chu, Myron},
title = {A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis},
journal = {Arthritis Research & Therapy},
year = {2024},
doi = {10.1186/s13075-024-03337-2}
}
EUVIMED